Tag:
Japan
Latest Headlines
Latest Headlines
Eisai renews focus on 'more attractive' Japan
Eisai is coming to believe that there's no place like home. The Japanese drugmaker says it's planning to pull back in the U.S. and refocus on East Asia, and not just because markets such as...
Scoring winners and losers in Japan pharma M&A bout
Japan's biggest pharma players have been roaming the world in recent years in a restless search for new acquisitions. They've been looking for deals to put an extra oomph into their earnings. Now The
Astellas scores highest in Japanese M&A bout
Japan’s biggest pharma players have been roaming the world in recent years in a restless search for new acquisitions. They've been looking for deals to put an extra oomph into their earnings.
Lilly's Lechleiter sees pharma clouds abroad
Eli Lilly ($LLY) CEO John Lechleiter (photo) says price squeezes in Europe and Japan will be key challenges to his company's sales in 2012, one week after the company predicted a bigger-than-expected
Whose sales reps get the highest ratings--and where?
The "do not disturb" signs may be out for pharma reps at more U.S. medical practices these days. But according to a new study by Cegedim Strategic Data, sales reps are almost as popular with doctors
Lupin expands Japanese reach with I'Rom buy
India's Lupin has made a second foray into Japan, striking a deal to buy the Tokyo-based injectables maker I'Rom Pharmaceutical. The buyout follows Lupin's acquisition of Kyowa Pharmaceuticals, which
Given Imaging starts pivotal trial for PillCam COLON 2 in Japan
Israel's Given Imaging ($GIVN) has begun the pivotal PillCam COLON 2 study to support its planned regulatory submission to Japan's Pharmaceuticals and Medical Devices Agency. The study will evaluate
Private equity looks for $905M in sale of Japan's Showa
Looking for a local beachhead in Japan? Private equity firm Tokio Marine Capital is looking to sell the drugmaker Showa Yakuhin Kako in a deal that could bring in as much as $905 million, sources
Pfizer, Roche, Novartis lead the way in Japan
As Japanese drugmakers look outside their home market for acquisitions and growth, Big Pharma is moving in. With sales growth slowing to a crawl in the U.S. and Europe, global drugmakers have...
Japanese clear Novartis' Gilenya, Vertex's hep C drug
Japanese regulators approved two important new drugs: Novartis's Gilenya, the first oral multiple sclerosis treatment, and Vertex Pharmaceuticals's Telavic, the hepatitis C treatment sold as Incivek
